A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).

Novartis Investigative Site, Budapest

Novartis Investigative Site, Geneva

Novartis Investigative Site, Basel

Novartis Investigative Site, Debrecen

Novartis Investigative Site, Yvoir

Novartis Investigative Site, Kaposvár

Novartis Investigative Site, Bruges

Novartis Investigative Site, Sankt Gallen

Memorial Sloan Kettering Sloan Kettering 2, New York

Novartis Investigative Site, Bangkok

Novartis Investigative Site, Bangkok

Novartis Investigative Site, Madrid

Novartis Investigative Site, Málaga

Medical University of South Carolina -Hollings Cancer Center MUSC, Charleston

Georgia Health Sciences University Dept. of MCG, Augusta

Cleveland Clinic Foundation Cleve Clinic, Cleveland

Goshen Center for Cancer Care IU Cancer Center, Indianapolis

Novartis Investigative Site, Florence

Novartis Investigative Site, Frankfurt

University of Kansas Hospital and Medical Center SC - Univ KS, Kansas City

University of Texas MD Anderson Cancer Center Dept of MD Anderson (16), Houston

Novartis Investigative Site, Freiburg im Breisgau

Novartis Investigative Site, Reggio Calabria

Novartis Investigative Site, Bobigny

Dana Farber Cancer Institute Beth Israel Deaconess Med Ctr, Boston

Novartis Investigative Site, Innsbruck

Novartis Investigative Site, Vienna

Novartis Investigative Site, Edmonton

Novartis Investigative Site, Toronto

Novartis Investigative Site, Szeged

Novartis Investigative Site, Roma

Novartis Investigative Site, Seoul

Novartis Investigative Site, Seoul

Novartis Investigative Site, Barcelona

Novartis Investigative Site, Gothenburg

Novartis Investigative Site, Stockholm

Novartis Investigative Site, London

Novartis Investigative Site, Wolverhampton